Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma 138Lymphoma, Non-Hodgkin 84Lymphoma, Large B-Cell, Diffuse 83Small Cell Lung Carcinoma 78Hodgkin Disease 61Precursor Cell Lymphoblastic Leukemia-Lymphoma 59Leukemia 57Burkitt Lymphoma 56Lung Neoplasms 49Lymphoma, Follicular 47Lymphoma, Mantle-Cell 44Leukemia, Myeloid, Acute 41Lymphoma, Large-Cell, Immunoblastic 40Multiple Myeloma 33Leukemia, Lymphocytic, Chronic, B-Cell 33Carcinoma, Non-Small-Cell Lung 30Recurrence 26Neuroblastoma 25Lymphoma, B-Cell, Marginal Zone 25Central Nervous System Neoplasms 24Ovarian Neoplasms 18Sarcoma 17Brain Neoplasms 17Dendritic Cell Sarcoma, Interdigitating 16Congenital Abnormalities 16Lymphoma, Large-Cell, Anaplastic 15Breast Neoplasms 15Testicular Neoplasms 14Neoplasms, Plasma Cell 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13

Interventions

tislelizumab 1selinexor 1atezolizumab 1anlotinib 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Extensive Stage Lung Small Cell Cancer × Etoposide × Clear all
NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
165 enrolled

Extensive Stage Lung Small Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡